Vertex Kidney Drug Hits Phase 3 Mark — BLA Submission Expected by End of March

By FieldPulse Staff · March 17, 2026

Tags: launch, strategy

Vertex Phase 3 RAINIER trial shows 52% proteinuria reduction with povetacicept in IgAN. BLA submission by end of March 2026; potential approval November 2026.

Vertex Pharmaceuticals announced positive results from its Phase 3 RAINIER trial in IgA nephropathy (IgAN) on March 17, 2026.

Its drug povetacicept — a dual inhibitor of BAFF and APRIL cytokines — achieved its primary endpoint, showing a 52% reduction from baseline in urine protein-to-creatinine ratio and a 49.8% placebo-adjusted reduction (p<0.0001).

The drug also resolved hematuria (blood in urine, a key disease marker) in 85% of treated patients.

Vertex said it plans to complete its rolling BLA submission to the FDA by end of March 2026, with analysts estimating a potential approval as early as November 2026.

The data puts Vertex in a strong position in IgAN, a rare progressive kidney disease with limited treatment options.

The company's entry diversifies its portfolio beyond cystic fibrosis, where its Trikafta franchise dominates.

For reps watching the rare kidney disease space, the approval timeline puts potential launch activity in Q4 2026.

Source: https://www.biopharmadive.com/news/vertex-povetacicept-iga-nephropathy-study-results/814253/